Senti Biosciences, Inc.

The Biotech Patient In one of David Poyer’s novels on the career of a fictional US naval officer, a regional war erupts and politicians consult with academics on how such conflicts are resolved. While

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Menarini, SciClone Will Partner On

The market for initial public offerings by biopharmaceutical companies declined to just 22 IPOs in the US in 2022 and it has gotten off to a slow start in 2023 with just three small offerings to date,

Plummeting stock prices for biotechnology companies and declining valuations across the industry were common topics at the BIO International Convention 13-16 June in San Diego. However, attendees also